Cough Drops Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Regulatory and licence map for this cough drops project

The regulatory architecture for cough drops manufacturing in India is layered across food safety, drug equivalence, labelling, and environmental compliance. Determining whether a formulation qualifies as a 'food product' under FSSAI or a 'drug' under the Drugs and Cosmetics Act is the foundational licensing decision, and misclassification is the most common reason for licence rejection in this sub-sector.

• FSSAI State Licence under the Food Safety and Standards (Licensing and Registration of Food Business) Rules, 2011: mandatory for manufacturing with annual turnover exceeding ₹12 lakh; application via FoSCoS portal; requires layout plan, equipment list, and FSMS implementation (based on Codex CAC/RCP 1-1969).
• BIS Certification under IS 5219 (Specification for Loothy Drops / Medicated Lozenges): voluntary but operationally essential for institutional and modern-trade supply; carries a ₹15,000–₹25,000 testing fee per variant; certification requires BIS-approved laboratory test reports for moisture, hardness, and active ingredient uniformity.
• CDSCO Form CT-20 (Clinical Trial Certificate) or import licence under Schedule Y of the Drugs and Cosmetics Rules, 1945: required only if the formulation contains scheduled substances or makes therapeutic claims beyond the Food Safety and Standards Act thresholds; products positioned purely as food or dietary supplements do not require CDSCO involvement.
• GST Registration under the GST Act, 2017: HS Code 1704.90 (Sugar Confectionery including cough drops) attracts 18% GST; separate GST registration required in the state of manufacture; ITC recovery on capital goods is permitted under the input tax credit mechanism.
• Pollution Certificate under the Water (Prevention and Control of Pollution) Act, 1974 and Air (Prevention and Control of Pollution) Act, 1981: applicable if the facility employs boiler/tfuel-based heat processing above 2 TPH; consent from the State Pollution Control Board (SPCB) required before FSSAI licence endorsement; EIA Notification 2006 applies if land area exceeds 20,000 sq ft.
• Factory Licence under the Factories Act, 1948 (as amended): mandatory for establishments employing 10 or more workers on any day with power, or 20+ workers without power; requires submission of stability certificate, health-and-safety plan, and CCTV coverage of processing areas.
• Employees' State Insurance (ESI) Registration under the ESI Act, 1948: applicable if the unit employs 10 or more persons; covers medical benefit, sickness benefit, and maternity benefit; employer contribution at 3.25% of wages.
• Employees' Provident Fund (EPF) Registration under the EPF & Miscellaneous Provisions Act, 1952: mandatory for establishments with 20 or more employees; employer's contribution at 13% of wages; digital challan through the EPFO Unified Portal.

KAMRIT Financial Services LLP manages the end-to-end filing of all eight statutory approvals, from FSSAI licence procurement through the FoSCoS portal to SPCB consent applications and BIS testing coordination. Our regulatory team maintains established liaison relationships with FSSAI regional offices, BIS zonal branches, and State Pollution Control Boards in Gujarat, Maharashtra, and Himachal Pradesh, where the majority of food processing approvals are processed within statutory timelines.

Sectoral context for this cough drops project

The cough drops sub-sector sits at the intersection of food processing and OTC healthcare, a positioning that generates distinct demand dynamics from adjacent categories such as hard-boiled candy, medicated syrups, and herbal teas. Within the sub-sector, four distinct product segments carry differentiated growth rate gradients: medicated lozenges (chlorhexidine and ambroxol-based formulations) growing at 9–11% CAGR, driven by pharmacist recommendation and clinical endorsements; Ayurvedic-herbal drops (mulethi, tulsi, ginger-based) growing at 15–18% CAGR, benefiting from the broader AYUSH acceptance wave and FSSAI's liberalised composite food categorisation; sugar-free and diabetic-appropriate variants growing at 18–22% CAGR, a nascent but fast-accelerating segment targeting the urban diabetic and pre-diabetic consumer base; and premium flavoured drops (honey-lemon, mint, berry) growing at 13–16% CAGR, driven by up-trading in modern trade and quick-commerce channels. The organised retail penetration increase from approximately 18% to an estimated 28% by 2030 is disproportionately benefiting the herbal and premium segments, where brand presentation and shelf-appeal carry higher weight than in traditional medicated lozenges.

Quick-commerce platforms (Swiggy Instamart, Zepto, Blinkit) have introduced a new consumption occasion: the 'immediate sore-throat remedy' purchase, which commands a price premium of 18–25% over equivalent kirana-store purchases and is accelerating repeat-purchase frequency among metro and Tier-1 consumers. The export demand from GCC and SE Asia diaspora markets adds a third vector of growth, with sugar-free variants being particularly sought after in GCC markets where diabetes prevalence exceeds 20% of the adult population. The project report addresses each segment's margin profile and recommends a product-mix strategy that allocates 40% capacity to Ayurvedic-herbal variants, 30% to medicated lozenges, 20% to premium flavoured drops, and 10% to sugar-free variants at launch.

Project-specific demand drivers

• Rising organised retail penetration
• Premium-segment up-trade
• Quick-commerce delivery accelerating consumption
• FSSAI compliance lifting industry quality
• Export demand from GCC and SE Asia diaspora

Technology and machinery benchmarks

Cough drops manufacturing technology spans two principal process routes: the batch cooking method and the continuous automatic cooking extrusion method. For a project with CapEx in the ₹1.8–13 crore band, KAMRIT recommends the semi-automatic batch cooking line with integrated forming and blister packaging for the ₹1.8–4 crore scale, and a fully automatic continuous extrusion line with servo-driven blister packaging for the ₹6–13 crore scale. Key equipment vendors in the Indian market include A.

R. Engineering Works (Ludhiana) and Baker Engineering (Delhi NCR) for candy cookers and forming machines; Rachana Group (Ahmedabad) for blister packaging lines with serialization capability; and international suppliers such as Roberts Tapputi (UK) and Loesch Verpackungstechnik (Germany) for high-throughput lines above ₹8 crore CapEx. Chinese equipment from Jiangsu Zhongyin and Guangzhou Huangshi offers 30–40% lower capital cost but carries higher spare-parts lead times of 6–8 weeks and non-compliance risk with FSSAI machinery standards if not BIS-evaluated.

Japanese suppliers such as Tanaka and Fresco Systems offer intermediate positioning with energy efficiency guarantees. CapEx benchmarks for a 2 TPD (tonnes per day) facility: continuous cooking extruder at ₹28–35 lakh, automatic blister packaging line (4-lane) at ₹45–60 lakh, candy batch cooker and forming table at ₹18–25 lakh, reverse osmosis water treatment plant at ₹12–18 lakh, and auxiliary utilities and electricals at ₹20–30 lakh, totalling ₹4.2–5.8 crore for the medium-scale configuration. Energy consumption averages 380–420 kWh per tonne of finished product, with thermal energy (LPG/PNG) contributing an additional ₹8–12 per kg of output.

Moisture control during the forming stage is the critical quality parameter: target moisture of 2.5–3.5% by weight must be maintained to achieve the requisite shelf stability of 18 months under accelerated stability testing conditions. Conversion cost (packaging labour, energy, and overheads) ranges from ₹18–28 per 100g pack across the CapEx spectrum, with the lower figure achievable at full capacity utilisation above 78%.

Bankable Means of Finance for this cough drops project

KAMRIT recommends a Debt:Equity ratio of 65:35 for projects in the ₹6–13 crore CapEx band and 55:45 for projects below ₹4 crore, reflecting the asset-backed nature of the facility and the working-capital intensity of inventory management in the FMCG channel. For the ₹6 crore mid-scale scenario, the means of finance break down as follows: term loan from State Bank of India (SBI) or HDFC Bank under their Food Processing Scheme at 9.5–10.75% ROI, constituting approximately ₹3.6 crore; SIDBI's Food Processing Fund offering ₹1.2 crore at 8.75–9.5% with a 7-year tenor; promoter equity at ₹1 crore; and a working-capital facility of ₹1.2 crore from the consortium banker's Cash Credit limit at MCLR + 75–150 bps. PMEGP (Prime Minister's Employment Generation Programme) administered through KVIC is applicable for units below ₹2 crore with a project cost subsidy ceiling of ₹1 lakh per seat for general category and ₹1.5 lakh for SC/ST/Women, though the subsidy is released post-disbursement milestone and is not netted from the loan principal. CGTMSE (Credit Guarantee Fund Trust for Micro and Small Enterprises) cover is available for the term loan tranche, reducing the effective risk weight for the lending bank and enabling collateral-free borrowing up to ₹5 crore. State MSME schemes in Gujarat (Mudra Plus), Maharashtra (Maharashtra State Innovation Society), and Himachal Pradesh (HIMCARE food processing subsidy) offer additional top-up grants of 5–10% of CapEx, and KAMRIT's financial structuring team coordinates applications concurrently with the bank loan process. Working-capital cycle is estimated at 48–55 days: raw material inventory (12 days at 18–20 days' stock), production cycle (5–7 days), finished goods (15–18 days), and trade receivables (20–22 days against kirana distributors, 7–10 days against modern trade). Sensitivity analysis on the ₹6 crore base case shows EBITDA margin ranging from 18.2% at 60% capacity utilisation to 26.8% at 90% utilisation, with the payback period ranging from 4.9 years (60% utilisation) to 3.2 years (85% utilisation and above).

Risks and mitigation for this project

Three risks carry the highest materiality for this project. First, raw-material price volatility for key inputs including sugar (linked to ISMA retail indices), medical-grade glucose syrup, mulethi extract, and blister-grade PVC/APFC film creates margin compression risk of 200–350 basis points per ₹8–10 per kg swing in sugar prices. The bankable DPR addresses this through a rolling 90-day forward purchase contract for sugar via institutional commodity exchanges (NCDEX) and a cost-plus pricing clause in modern-trade supply agreements that resets input costs semi-annually.

Second, channel substitution risk arises from private-label cough drop ranges launched by large modern-trade chains (Reliance Retail, BigBasket) at 30–40% lower price points, which could erode the project's pricing architecture in the medicated and herbal segments. The mitigation structure includes a dedicated pharmacy and hospital channel strategy that carries 15–20% higher margins and is less susceptible to private-label competition, alongside brand investment in AYUSH positioning that aligns with FSSAI's evolving quality standards under Schedule M comparables. Third, regulatory reclassification risk exists if the FSSAI or CDSCO re-categorises certain herbal formulations as drugs under the Drugs and Cosmetics Act, triggering a higher compliance burden including Schedule M factory upgrades and CDSCO licensing.

The DPR's sensitivity analysis models a +₹0.8 crore CapEx requirement and a 6-month revenue delay under this scenario, with the financial model demonstrating debt-service coverage ratio (DSCR) remaining above 1.35 even under the stress case at 70% capacity utilisation in Year 3.

How to engage with KAMRIT on this report

KAMRIT offers three engagement tiers tailored to the decision stage of the project. Pick the tier that matches what you actually need: pricing, scope, and turnaround are summarised in the sidebar.

City-specific versions of this report